Fulya ÇİYİLTEPE, Kemal Tolga SARAÇOĞLU, Elif BOMBACI, Ersin KAHRAMAN, Ayten SARAÇOĞLU, Yeliz BİLİR

Covid 19'un Yoğun Bakım Yönetiminde Uzatılmış Hidroksiklorokinin Sağkalım ve Maliyetler Üzerindeki Etkisi

GİRİŞ ve AMAÇ: Hidroksiklorokin, çoğu koronavirüse ve özellikle SARS-CoV-2 dahil olmak üzere virüslere karşı geniş bir etki yelpazesi vardır. Ulusal tedavi kılavuzlarındaki hidroksiklorokin tedavi önerisi pandeminin başlangıcında 5 gün iken, 14 Nisan'dan itibaren hidroksiklorokin tedavisi altında kliniğin kötüleştiği durumlarda 10 gün olarak önerilmiştir. Bu retrospektif, gözlemsel, tek merkezli çalışmada, yoğun bakımda COVID-19 ile izlenen hastalarda hidroksiklorokin tedavi süresinin hastanede kalış günü, mekanik ventilasyon gereksinimi, süresi, sağkalıma ve maliyet üzerine etkisinin ortaya çıkarılması amaçlanmıştır.YÖNTEM ve GEREÇLER: Etik Kurul onayının ardından 5 gün süreyle hidroksiklorokin alan ilk 50 hastanın (Grup 1) ve 10 gün alan ilk 50 hastanın (Grup 2) verileri çalışmaya dahil edildi. Hastaların yaşı, cinsiyeti, ek hastalıkları, COVID-19 testleri, hidroksiklorokin tedavi günleri, invazif mekanik ventilatör ihtiyacı ve süresi, yoğun bakımda yatış günü, mortalite varlığı ve maliyetleri kaydedildi.BULGULAR: Grup 2'deki hastaların hastanede kalış süresi grup 1'den daha uzundu (9,4 güne karşı 13,8 gün, p = 0

The Effect of Extended Hydroxychloroquine in Intensive Care Management of Covid 19 on Survival and Costs

INTRODUCTION: There is a broad spectrum of action against most coronaviruses and especially viruses, including SARS-CoV-2. While the hydroxychloroquine treatment recommendation in the national treatment guidelines was 5 days at the beginning of the pandemic, it was recommended as 10 days in cases where the clinic deteriorated under hydroxychloroquine treatment since 14 April. In this retrospective, observational, single-center study, it was aimed to reveal the effect of hydroxychloroquine treatment duration on the day of hospitalization, mechanical ventilation requirement, duration, survival and cost in patients with COVID-19 in intensive care unit.METHODS: Following the approval of the Ethics Committee, the data of the first 50 patients (Group 1) who received hydroxychloroquine for 5 days and the first 50 patients (Group 2) who received 10 days were included in the study. Patients' age, gender, additional diseases, COVID-19 testings, hydroxychloroquine treatment days, invasive mechanical ventilator requirement and duration, intensive care hospitalization day, mortality and costs were recorded.RESULTS: The duration of hospitalization in patients in group 2 was longer than group 1 (9,4 days vs 13,8 days, p=0

PDF

___

1. Zhou P., Yang XL., Wang XG., Hu B., Zhang L., Zhang W., et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020;579; 270–273. DOI: 10.1038/s41586-020-2012-7
2. Chen N., Zhou M., Dong X, Qu J., Gong F., Han Y., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395;507–513 DOI: 10.1016/S0140-6736(20)30211-7
3. Burkard C., Verheije M.H., Wicht O., vanKasteren S.I., vanKuppeveld F.J., Haagmans B.L., et. al. Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoSPathog 2014;10 DOI: 10.1371/journal.ppat.1004502
4. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., et. al.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30;269-271. DOI:10.1038/s41422-020-0282-0
5. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral efects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 55(5):105938. DOI:10.1016/j.ijantimicag.2020.105938 Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12. DOI: 10.3171/2014.12.focus14748
7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Efects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722–7. DOI: 10.1016/s1473-3099(03)00806-5
8. Gautret P., Lagier JC., Parola P., Hoang VT., Meddeb L., Mailhe M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. J Antimicrob Agents 2020;20;105949. DOI: 10.1016/j.ijantimicag.2020.105949
9. J M Molina 1, C Delaugerre 2, J Le Goff 2, B Mela-Lima 3, D Ponscarme 3, L Goldwirt, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med et Mal Infect 2020; 50(4):384. DOI: 10.1016/j.medmal.2020.03.006
10. Chen J, Ping L, Liu, L, et al. A pilot study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease-19 (COVID-19). J ZheJiang University (Medical Sciences) 2020; 49(1):0-0.
11. Chen Z., Hu J., Zhang Z., Jiang S., Han S., Ya D., et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020 doi: 10.1101/2020.03.22.20040758
12. Olano J., Howland MA., Su MK., Hoffman RS., Biary R.. Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med 2019;37:2264.e5-2264.e8. DOI: 10.1016/j.ajem.2019.158387
13. Marmor, M. F., R. E. Carr, M. Easterbrook, W. F. Mieler, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377–1382. DOI: 10.1016/s0161-6420(02)01168-5
14. Wolfe, F., M. F. Marmor. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 2010; 62:775–784. doi:10.1002/acr.20133.
15. Stein, M., M. J. Bell, L. C. Ang. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 2000;27:2927–2931. PMID: 11128688
16. Ministry of Health: COVID-19 (SARS-CoV-2 Infection) Guide Scientific Committee Study. March 25, 2020. Available from: https://covid19bilgi.saglik.gov.tr/tr/covid-19-rehberi.html
17. T. C. Ministry of Health: COVID-19 (SARS-CoV-2 Infection) Guide Scientific Committee Study. April 14, 2020. Available from: https://covid19bilgi.saglik.gov.tr/tr/covid-19-rehberi.html
18. Jie Z., Hu HH. Zhi XZ.. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. 2020,43(03) : 185-188. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.009
19. Rijksinstituut voor Volksgezondheid en Milieu Ministerie van Volksgezondheid, Welzijn en Sport 2020 (Accessed on 6th March ): Avaible from: https://lci.rivm.nl/covid-19/bijlage/behandeladvies.
20. Linee guida sullagestione terapeutica e di supportoper pazienti con infezioneda coronavirus COVID-19. Società Italiana di Malattie Infettive e Tropicali 2020 (Accessed on 6th March). Avaible from: http://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf.
21. Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;ciaa237. DOI: 10.1093/cid/ciaa237
22. Million M., Lagier JC., Gautret P., Colson P., Fournier PE., Amrane S., et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;35:101738. DOI: 10.1016/j.tmaid.2020.101738
23. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3
24. Bartsch SM., Ferguson MC., McKinnell JA., O'Shea KJ., Wedlock PT., Siegmund SS., et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 InThe United States. Health Aff (Millwood). 2020; 39(6):927-935. DOI: 10.1377/hlthaff.2020.00426.